Skip to content

Vagal Nerve Stimulation for Interoception Modulation

Modulation of Gastric Sensitivity and Accommodation by Vagal Nerve Stimulation

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03603730
Enrollment
25
Registered
2018-07-27
Start date
2023-07-11
Completion date
2026-03-31
Last updated
2026-07-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Adult

Brief summary

Explore the effects of variable ingested volumes and auricular transcutaneous vagal nerve stimulation (taVNS) on brain and stomach outcomes in healthy adults.

Detailed description

We aim to assess and modulate gastric interoception in healthy adults using gastric and brain MRI, different meal volumes (Experiment 1), and transcutaneous auricular vagus nerve stimulation (taVNS) (Experiment 2). MR examinations will precede and immediately follow ingestion of a test meal (containing pineapple, with high manganese content, as a contrast agent), using real-time 3D cine MRI. Subjects will be scanned before ingestion and at 15, 45, and 75 minutes post-meal, in order to extract objective indices of gastric function. Functional MRI (fMRI) brain scans will be alternated to gastric MRI scans. Each subject will undergo 2 separate MRI visits, ingesting different doses of contrast meal in order to peripherally modulate gastric afference (Experiment 1), or receiving sham and active taVNS (Experiment 2), so to modulate visceral afference at the central level.Outcomes will assess the taVNS response of brainstem vagal neurocircuitry, as well as the impact of taVNS on fMRI connectivity patterns (fcMRI) of gastric afference, and link them to MRI-derived gastric outcomes, such as gastric emptying rate, gastric accommodation (fundic volumes), and gastric motility (peristaltic wave propagation).

Interventions

DEVICEtaVNS

Active taVNS delivered to the external ear at a moderate, non-painful level.

DEVICESham taVNS

Sham taVNS delivered to the external ear using zero-current.

Sponsors

Massachusetts General Hospital
Lead SponsorOTHER
National Center for Complementary and Integrative Health (NCCIH)
CollaboratorNIH

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Male and female patients aged 18 and 65 years old (inclusive) * Comprehension of instructions * Avoidance of alcohol, nicotine, and caffeine for 25 hours prior to study session

Exclusion criteria

* BMI (Body Mass Index) more than 32 and/or weight \> 235 lbs. (limits of the MRI table) * Any other significant medical disease (systemic or CNS), psychiatric disorder, or chronic pain condition/s * Epilepsy or a prior history of seizures * Psychotropic medications or other medications that effect neurovascular coupling (i.e. fMRI) * Subjects taking illicit drugs or opioids * Allergy to pineapple (used in the test meal during MRI) * Contraindications for MRI: High magnetic fields may pose a serious health hazard to subjects with implanted ferromagnetic objects. Every subject in this study will be carefully screened before entering the high magnetic field shielded room to collect a precise outline of the subject's medical history. Subjects with the following characteristics/disease will not be eligible to participate in the study: -History of Head Trauma -Any metallic implants (e.g. braces or permanent retainers) -Tattoos with metallic ink above the nipple line -Surgical Aneurysm Clips -Cardiac Pacemaker -Prosthetic Heart Valve -Neurostimulator -Implanted pumps -Cochlear Implants -Metal rods, Plates -Screws -Recent Previous Surgery -IUD -Hearing Aid -Dentures (which might create NMR artifacts) -Metal Injury to eyes -Pregnancy or plans to become pregnant -Breast Feeding -Meniere's Disease -Transdermal (skin) patches such as NicoDerm (nicotine for tobacco dependence), Transderm Scop, or Ortho Evra (birth control) -Non-normally cycling females -Claustrophobia

Design outcomes

Primary

MeasureTime frameDescription
NeuroimagingVisits 1,2,3 (2 hours)NTS connectivity
Gastric FunctionVisits 1,2,3 (2 hours)MRI-derived measures of gastric accommodation

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORRoberta Sclocco, PhD

Spaulding Rehabilitation Hospital

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 7, 2026